Bone Health and Densitometry Screening in Transgender and Gender Diverse People

Session approved for 1 ASRT Category A Credit
Session approved for up to 1 AMA PRA Category 1 Credits™

This session duration is 50 minutes.

Transgender and gender diverse people may take gender affirming hormone therapy to affirm their gender identity and to improve quality of life and well-being. Very little is known about the impact of gender affirming hormone therapy on skeletal health in this population. Will discuss screening for low bone mass in this population prior to and after receipt of gender affirming hormone therapy and the available data on gender affirming hormone therapy on skeletal health.

Learning Objectives:

  • Define transgender identity and the prevalence of transgender identity
  • Identify reasons to perform bone densitometry screening in transgender and gender diverse people
  • Describe risk factors for low bone density in transgender and gender diverse people

Vin Tangpricha, MD, PhD

Division of Endocrinology, Metabolism & Lipids

Emory University School of Medicine

Vin Tangpricha, MD, PhD, Professor of Medicine, Emory University School of Medicine Vin Tangpricha is a Professor of Medicine and program director for the endocrinology fellowship program in the Division of Endocrinology, Metabolism and Lipids at Emory University School of Medicine in Atlanta, Georgia. Dr. Tangpricha received his medical degree from Tufts University School of Medicine and completed his internal medicine residency and endocrinology fellowship at Boston University Medical Center. He completed his Ph.D. degree in molecular medicine on the topic of vitamin D at Boston University School of Medicine. He serves on the Endocrine Society guidelines committee for the hormone treatment of gender-non-conforming and gender incongruent patients, which has published two international guidelines on transgender patients (2009 and revised in 2017). He served on the World Professional Association for Transgender Health guidelines for the Standards of Care (SOC) for Transgender people in 2011 (SOC7) and currently serves as the chair of the hormone chapter an updated guideline, SOC8. He served as a committee member for the 2019 ISCD official position statement on bone densitometry measurement in transgender and gender non-conforming people. He is the immediate past-president of the World Professional Association for Transgender Health (WPATH). He has received funding from the Cystic Fibrosis Foundation and NIH. He has published over 250 peer reviewed manuscripts on transgender medicine, vitamin D and cystic fibrosis.

Disclosures: No relationships to disclose.

Rachel Hopkins, MD (Moderator)

Associate Professor of Medicine

Division if Endocrinology, State University of New York Upstate Medical University

Rachel Hopkins, MD is an Endocrinologist and Associate Professor at the State University of New York Upstate Medical University.  She currently serves as Director of the Transgender Program in the Division of Endocrinology as well as Program Director of the Fellowship in Endocrinology and Metabolism. She also serves as codirector of the endocrine and reproductive unit in the first-year medical school foundational science curriculum.  Clinical interests include medical care of transgender people, pituitary disorders, osteoporosis, diabetes, and health equity.

Disclosures: No relationships to disclose.

Key:

Complete
Failed
Available
Locked
Recorded Archive
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin.
Session
04/01/2022 at 5:25 PM (EDT)   |  50 minutes
04/01/2022 at 5:25 PM (EDT)   |  50 minutes
Survey
10 Questions
Medical Certificate
Up to 1.00 medical credits available  |  No certificate available
Up to 1.00 medical credits available  |  No certificate available